

## 2020 China Cancer Immunotherapy Workshop

In-person in Beijing, China and Virtual in US and Europe

October 15-16, 2020 (US Eastern Time)

<b>October 15, 2020 (Thursday)</b>		
Times	Titles	Speakers
08:30 PM	Opening Remarks	
<b>08:40-10:05 PM</b>	<b>Conference Main Theme Session: New Horizon of Cancer Immunotherapy</b> <b>Session Chairs:</b> Wenru Song (Kira Pharmaceuticals/CAHON), Ke Liu (US FDA/CAHON)	
08:40-09:05 PM	Cell Transfer Immunotherapy for Cancer (20 min + 5 min Q&A)	Steve Rosenberg, MD. NIH
09:05-9:30 PM	Visionary Change in Cancer Immunotherapy From Enhanced Immunity to Normalization of Immunity (20 min + 5 min Q&A)	Lieping Chen, MD. Yale University/CAHON
09:30-09:55PM	Regenerative Medicine Advanced Therapy (20 min + 5 min Q&A)	Ke Liu, MD, PhD. US FDA/CAHON
09:55-10:05 PM	Coffee and Tea Break	
<b>10:05-11:45 PM</b>	<b>Session 1: Biomarkers for Cancer Immunotherapy</b> <b>Session Chairs:</b> Siwen Hu-Lieskovan (University of Utah/CAHON), Lei Zheng (Johns Hopkins University/CAHON)	
10:05-10:30 PM	PD-L1 and Responses to Immune Checkpoint Inhibitors (20 min + 5 min Q&A)	Janis Taube, MD, Johns Hopkins University

10:30-10:55 PM	Genomic landscape and Immunotherapy (20 min + 5 min Q&A)	Valsamo Anagnostou, MD, Johns Hopkins University
10:55-11:20 PM	Biomarkers, Preclinical Studies and the Development of Combination Immunotherapy for metastatic Triple Negative Breast Cancer (20 min + 5 min Q&A)	Bernard Fox, PhD. Providence Cancer Institute
11:20-11:45 PM	Temporal and Spatial analysis of the tumor microenvironment (20 min + 5 min Q&A)	Garry Nolan, PhD. Stanford University
11:45PM-1:30AM	Lunch Break (China)	
<b>October 16, 2020 (Friday)</b>		
<b>1:30-3:00 AM</b>	<b>Session 2: Latest update on cancer immunotherapy from China</b> <b>Session Chairs:</b> CCFDIE	
1:30-2:00 AM	Research progress on cancer immunotherapy (25 min + 5 min Q&A)	Xin Lin , Tsinghua University
2:00-2:30 AM	Advanced in immunotherapy for Stomach Cancer in China(25 min + 5 min Q&A)	Lin Shen, Beijing Cancer Hospital
2:30-3:00AM	Scientific assessment of autologous T cell immunotherapy value in clinical tumor treatment (25 min + 5 min Q&A)	Jun Ren, Beijing Shijitan Hospital
3:00-3:10 AM	Coffee and Tea Break	
<b>3:10-5:00AM</b>	<b>Session3: Perspective from Biopharma Industry</b> <b>Session Chairs:</b> Ruirong Yuan (Novartis/CAHON), Ben Yong (BeiGene/CAHON)	

3:10-3:30 AM	TBD	David Raben, Genentech
3:30-3:50 AM	ASTELLAS IMMUNO-oncology strategy and key success factors	Peter Sandor, Astellas
3:50-4:00 AM	Dual immunotherapy in 1 <sup>st</sup> line advanced NSCLC and Malignant Pleural mesothelioma: Example of Nivolumab and Ipilimumab Development Program combination	Abderrahim Oukessou, BMS
4:00-4:10 AM	I-Mab tumor immunotherapy pipeline and CD47 antibody innovation experience	Jingwu Zang, I-MAb
4:10-4:20 AM	IO Perspective from Genor Biopharma	Tong Li, Genor
4:20-4:30 AM	Mechanistic basis of PD-1/PD-L1 inhibitors	Wei Xu, Innovent
4:30-4:40 AM	BeiGene Pipeline	Lai Wang, BeiGene
4:40-4:50 AM	Akesobio: Research and Exploration in the Field of Tumor Treatment	Xia Yu, Akesobio
4:40-5:00 AM	Powerful combination: SPH-BIOPAD's innovative tumor immunotherapy R&D road	Haijin Meng Shanghai Pharma-BIOPAD

<b>October 16, 2020 (Friday)</b>		
Times	Titles	Speakers
<b>8:30-10:10 PM</b>	<b>Session 4: Combination Immunotherapy</b> <b>Session Chairs:</b> Chongxian Pan (Harvard University/CAHON), Tianhong Li (University of California, Davis/CAHON)	

08:30-8:55 PM	Combination strategy of overcoming the resistance to immune checkpoint inhibitor (20 min + 5 min Q&A)	Charles Drake, MD, PhD. Janssen Biopharmaceutical
8:55-9:20 PM	Bintrafusp alfa, From bench to first-in-human to registration pathway studies of a bifunctional fusion protein targeting PD-L1 and TGF-beta (20 min + 5 min Q&A)	James Gulley, MD, PhD. NIH
9:20-9:45 PM	Novel targets in drug development for immuno-oncology (20 min + 5 min Q&A)	Jason Luke, MD. University of Pittsburg
9:45-10:10 PM	New progress in research on new tumor immunotherapeutic drugs (20 min + 5 min Q&A)	Yuankai Shi, MD. Cancer Hospital, Chinese Academy of Medical Sciences
10:10 PM-10:20 PM	Coffee and Tea Break	
<b>10:20 PM-12:00 AM</b>	<b>Session 5: Advances in Cell Therapy</b> <b>Session Chairs:</b> Zihai Li (Ohio State Univ/CAHON), Delong Liu (New York Medical College/CAHON)	
10:20-10:45 PM	T cell therapy for solid tumors (20 min + 5 min Q&A)	Prasad Adusumilli, MD, MSKCC
10:45-11:10 PM	Progress with CAR T Cells (20 min + 5 min Q&A)	Marcela Maus, MD, PhD, MGH/Harvard
11:10-11:35 PM	CAR-T Therapy for Mantle Cell Lymphoma (20 min + 5 min Q&A)	Michael Wang, MD Anderson Cancer Center
11:35 PM-12:00 AM	Overcoming barriers to CAR-T cells in solid tumors (20 min + 5 min Q&A)	Stanley Riddell, MD, Fred Hutchinson Cancer Research Center
12:00 AM-1:30 AM	Coffee and Tea/Lunch Break	

<b>October 17, 2020 (Saturday)</b>		
<b>1:30-3:00 AM</b>	<b>Session 6: China Update on Cellular Therapy</b> <b>Session Chairs:</b> CDE	
1:30-2:00 AM	CAR T cell therapy for B-NHL	Jianfeng Zhou Tongji Medical College of Huazhong University of Science & Technology
2:00-2:30 AM	Immunotherapy for blood tumor in China	Jianxiang Wang, Blood Disease Hospital, CAMS
2:30-3:00 AM	The basic principles and practice of cell therapy for solid tumors	Weidong Han, PLA General Hospital
<b>3:00-5:00 AM</b>	<b>Session 7: Regulatory Considerations</b> <b>Session Chairs:</b> CDE	
3:00-3:20 AM	Cell therapy regulations: clinical pharma aspect	Wei Wei, CDE
3:20-3:40 AM	Cell therapy regulations: pre-clinical aspect	Min Zhang, CDE
3:40-4:00 AM	Cell therapy regulations: clinical trial aspect	Jianchao Gao, CDE

4:00-4:20 AM	Cell therapy regulations: special consideration for oncolytic virus	Yunhong Huang, CDE
4:20-5:00 AM	Panel discussions	